中国临床药理学杂志2025，Vol.41Issue(11)：1522-1526,5.DOI:10.13699/j.cnki.1001-6821.2025.11.005
阿戈美拉汀联合帕罗西汀治疗抑郁症伴失眠患者的临床研究
Clinical trial of agomelatine combined with paroxetine in the treatment of patients with depression and insomnia
摘要
Abstract
Objective To observe the clinical efficacy and safety of agomelatine combined with paroxetine tablets in patients with depression and insomnia,and its effects on neurotransmitter levels and sleep.Methods The patients with depression and insomnia were divided into control group and treatment group,according to random number table.Control group was treated with paroxetine tablets 20 mg,oral,treatment course was 8 weeks.Treatment group was treated with agomelatine 25 mg and paroxetine tablets 20 mg,once a day,treatment course was 8 weeks.The Hamilton depression rating scale(HAMD),Montreal cognitive assessment scale(MoCA),neurotransmitters[norepinephrine(NE),5-hydroxytryptamine(5-HT),dopamine(DA)],Pittsburgh sleep quality index(PSQI)and incidence of adverse drug reactions between two groups were compared.Results Treatment group was enrolled 60 cases;control group was enrolled 60 cases.After 8 weeks of treatment,the HAMD in treatment group and control group were(17.33±1.54)and(21.19±1.87)scores;MoCA were(29.01±0.19)and(28.52±0.21)scores;NE levels were(65.56±4.63)and(53.74±4.52)ng·mL-1;5-HT levels were(165.82±7.17)and(149.63±8.48)ng·mL-1;DA levels were(582.73±17.52)and(543.85±20.38)ng·mL-1,sleep latency were(1.09±0.12)and(1.53±0.15)scores;sleep efficiency were(1.12±0.17)and(1.58±0.20)scores;hypnotic drug were(1.01±0.13)and(1.42±0.15)scores;subjective sleep quality were(1.14±0.10)and(1.62±0.16)scorse;sleep persistence were(1.16±0.11)and(1.55±0.13)scores;the score for sleep disorders were(1.07±0.14)and(1.52±0.17)scores;daytime functional disorders were(0.99±0.16)and(1.51±0.18)scores,all with statistically significant difference(all P＜0.05).The adverse drug reactions in treatment group and control group were 11.67％and 8.33％,with no statistically significant differences(P＞0.05).Conclusion Administration of agomelatine and paroxetine tablets to patients with depression and insomnia can improve depressive symptoms,cognitive function,sleep conditions,regulate the expression of neurotransmitters such as NE and 5-HT,and has good safety.关键词
阿戈美拉汀片/帕罗西汀片/抑郁症/失眠/神经递质/睡眠Key words
agomelatine tablet/paroxetine tablet/depression/insomnia/neurotransmitters/sleep分类
医药卫生引用本文复制引用
王璐眉,陈晶,汪斌..阿戈美拉汀联合帕罗西汀治疗抑郁症伴失眠患者的临床研究[J].中国临床药理学杂志,2025,41(11):1522-1526,5.基金项目
浙江省医药卫生科技计划基金资助项目(2023KY1272) （2023KY1272）
